<DOC>
	<DOCNO>NCT02739139</DOCNO>
	<brief_summary>The manufacturer AlphaBRAIN ( TM ) claim product , take direct , beneficial effect cognition . The active ingredient AlphaBRAIN , Huperzine A , naturally occur compound find firmoss also think acetylcholinesterase inhibitor . Numerous clinical study undertake investigate effect Huperzine A cognition demonstrate benefit cognition individual diagnose neurodegenerative disease well performance academic task student . However , knowledge , randomize control trial evaluate effect AlphaBRAIN ( TM ) cognition . Thus , purpose current study assess effect daily oral administration AlphaBRAIN ( TM ) cognitive functioning , compare placebo , 45 day treatment . 1 . To evaluate single daily dose AlphaBRAIN ( TM ) v placebo give orally change battery standardize neuropsychological test ( see attach ) . 2 . A secondary objective evaluate single daily dose AlphaBRAIN ( TM ) v placebo give orally sleep .</brief_summary>
	<brief_title>Efficacy Study AlphaBRAIN Administered Orally</brief_title>
	<detailed_description />
	<criteria>Community dwell provide inform consent . MMSE score â‰¥ 26 . Body Mass Index within two standard deviation norm . Fluent English . Willing complete study assessment . Adequate visual auditory acuity allow neuropsychological testing . MMSE score &lt; 26 Body Mass Index great two standard deviation norm . Visual Auditory disability would interfere neuropsychological testing . No past diagnosis Stroke , ADD/ADHD , Learning Disability Cardiac Condition . No current life threatening illness . Not currently ( past 60 day ) take antidepressant psychoactive medication . Not currently take nonprescription cognitive enhancer ( nutraceuticals vitamins Ginko biloba . No history alcohol drug dependence define DSMIVTR .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>